PTC Therapeutics Promotes Matthew Klein, Eric Pauwels to C-Suite

Rare disease drug developer PTC Therapeutics (NASDAQ: [[ticker:PTCT]]) has promoted Matthew Klein to chief development officer. Klein joined the South Plainfield, NJ, biotech last year as global head of gene and mitochondrial therapies. He was previously CEO and chief medical officer of BioElectron Technology. PTC acquired some of BioElectron’s assets in 2019.

In other moves, PTC promoted Eric Pauwels to chief business officer. He joined PTC in 2015 as senior vice president and general manager of the Americas. PTC’s drug pipeline includes risdiplam, a spinal muscular atrophy drug developed with partner Roche. An FDA decision for that drug is expected in August.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan